Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
  • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
  • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/425—Thiazoles
  • A61K31/426—1,3-Thiazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/18—Antivirals for RNA viruses for HIV
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/20—Antivirals for DNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/20—Antivirals for DNA viruses
  • A61P31/22—Antivirals for DNA viruses for herpes viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
  • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
  • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
  • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D333/30—Hetero atoms other than halogen
  • C07D333/36—Nitrogen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
  • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
  • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
  • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Definitions

• RNase L pathway (Perelygin AA, Scherbik SV, Zhulin IB, Stockman BM, Li Y, Brinton MA. Proc Natl Acad Sci USA. 2002 JuI 9;99(14):9322-7).
• RNase L is activated during the interferon antiviral response by small, unusual oligoadenylates with 2',5'- internucleotide linkages (known as "2-5 A”) (Kerr IM, Brown RE Proc Natl Acad Sd USA.
• RNase L participates in the anti-cell proliferation activity of IFTSI (Hassel BA, Zhou A, Sotomayor C, Maran A, Silverman RH. EMBO J. 1993 Aug; 12(8):3297-304). 2-5 A induces through RNase L the degradation of ribosomal RNA (rRNA) and messenger RNA (mRNA), thereby reducing levels of protein synthesis, properties that if applied to aortic smooth muscle cells, could prevent restenosis following angioplasty.
• rRNA ribosomal RNA
• mRNA messenger RNA
• the invention is based on the discovery of a number of compounds which activate RNase L (see Example 3) (hereinafter the “disclosed RNase L activators"). These RNase L activators have antiviral activity (see Example 6) , including against Parainfluenza Virus 3 (HPIV3), Picornavirus and Encephalomyocarditis Virus (EMCV).
• the disclosed activators of RNase L also inhibit smooth muscle cell proliferation in vitro (see Example 7), and therefore have utility in treating . restenosis. It has also unexpectedly been found that the disclose RNase activators are not cytotoxic (Example 5). Based on these discoveries, novel RNase L activators, pharmaceutical compositions comprising these RNase L activators and methods of treatment with these RNase L activators are disclosed herein.
• Figures IA-I F are graphs showing the dose-response and kinetics of RNase L activation versus concentration in ⁇ M ( Figures 1 A-IC) or versus time in minutes ( Figures ID- IE) with 2-5 A or small molecule activators. Assays were by the RNase L FRET method and were performed at 22 0 C. (A 5 D) ppp(A2'p5'A) 2 , (B, E) Compound 1; and (C,F) Compound 2.
• Figure 2 shows the structures of small molecule activators of RNase L (Compounds 1-12) and their ECso concentrations required for 50% degradation in the RNA FRET probe. NA means no activity.
• Figures 6A-6B are graphs showing the cytotoxicity of Compounds 1 and 2 to HeIa M cells in an MTS conversion assay. The cytoxicity is measured by the absorbance at 490 nanometers versus concentration in ⁇ M on Day 1. The results for
• FIG. 1 shows results for HeIa M cells expressing RNase L;
• Figure 6B shows results for HeIa M cells expressing a nuclease-dead mutant of RNase L.
• Figure 7 shows photographs under inverted fluorescence microscope showing that Compound 2 suppresses replication of HPIV3/GFP.
• HeLa M cells deficient in RNase L were used as empty vector control cells, expressing wild type RNase L or in expressing a nuclease-dead mutant (R667A) RNase L. Pictures were captured using an inverted fluorescence microscope.
• Figure 8 is a bar graph showing the antiviral effect of compound 2 at varying concentrations in ⁇ M against encephalomyocardutus virus (EMCV), as measured by the number of plagues x 10 " .
• EMCV encephalomyocardutus virus
• a "subject” is preferably a human but can also be a veterinary animal, farm animal or laboratory animal in need of treatment for a viral infection, cancer or restensosis.
• Viral infections which can be treated with the disclosed RNase L activators include viruses with single-stranded RNA(s) for their genome.
• examples include orthomyxoviruses (e.g. influenza viruses), paramyxoviruses (e.g. respiratory syncytial virus & human parainfluenza virus-3), rhabdoviruses (e.g. rabies virus), togaviruses (e.g. rubella virus and eastern equine encephalitis virus), picornaviruses (e.g. poliovirus & Coxsackieviruses), flaviviruses (e.g. West Nile virus, Dengue virus, and hepatitis C virus), bunyaviruses (e.g.
• orthomyxoviruses e.g. influenza viruses
• paramyxoviruses e.g. respiratory syncytial virus & human parainfluenza virus-3
• rhabdoviruses e.g. rab
• the disclosed RNase L activators can also be used to treat infections from certain DNA viruses, including human papillomavirus, herpes simplex virus-1 and - 2, cytomegalovirus, and human herpesvirus-8. Additionally, the disclosed RNase L activators can also be used to treat infections from certain DNA viruses including Variola virus (smallpox virus), Monkeypox virus, Molluscum contagiosum virus, Epstein-Barr virus, adenovirus, varicella-zoster virus, human herpesvirus 6, human herpesvirus 7, B19 parvovirus, adeno-associated virus, BK virus, and JC virus as well.
• Variola virus smallpox virus
• Monkeypox virus Molluscum contagiosum virus
• Epstein-Barr virus Epstein-Barr virus
• adenovirus varicella-zoster virus
• human herpesvirus 6, human herpesvirus 7, B19 parvovirus adeno-associated virus, BK virus, and JC virus as well.
• cancers which can be treated with the disclosed RNase L activators include, but are not limited to, human sarcomas and carcinomas, e.g., fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma,
• the disclosed RNase L activators are commonly used to treat prostate cancer, ovarian cancer, brain cancer or bone cancer. Restenosis is a condition which can develop in blood vessels which have undergone coronary procedures or peripheral procedures with PTCA balloon catheters (e.g. percutaneous transluminal angioplasty). Restenosis is the development of scar tissue from about three to six months after the procedure and results in narrowing of the blood vessel. Restenosis is caused excessive smooth muscle proliferation. Because the disclosed RNase L activators inhibit smooth muscle proliferation, it is believed that these compounds can be used to inhibit, treat and/or prevent restenosis.
• aralkyl includes carbocyclic aromatic rings and heteroaryl rings.
• aromatic group may be used interchangeably with the terms “aryl”, “aryl ring” “aromatic ring”, “aryl group” and “aromatic group”.
• Aralkyl is an alkyl group substituted with an aromatic group.
• Phenalkyl is an alkyl group substituted with a phenyl group.
• a "monocyclic aromatic group” is an aromatic group with only one ring.
• Carbocyclic aromatic ring groups have only carbon ring atoms and include monocyclic aromatic rings such as phenyl.
• Examples of monocyclic heteroaryl groups include 2- furanyl, 3-furanyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 3- isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxadiazolyl, 5-oxadiazolyl, 2-oxazolyl, A- oxazolyl, 5-oxazolyl, 3-pyrazolyl, 4-pyrazolyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2- pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 3- pyridazinyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-triazolyl, 5-triazolyl, tetrazolyl, 2- thienyl and 3-thienyl.
• a “substitutable ring carbon atom” in an aromatic group is a ring carbon atom bonded to a hydrogen atom.
• the hydrogen can be optionally replaced with a suitable substituent group.
• the te ⁇ n "substitutable ring carbon atom” does not include ring carbon atoms which are shared when two rings are fused.
• “substitutable ring carbon atom” does not include ring carbon atoms .when the structure depicts that they are already attached to a moiety other than hydrogen.
• an aralkyl group has a certain number of carbon atoms
• it is to be understood that it is the number of carbon atoms in the alkyl portion of the aralkyl that is being specified.
• a C1-C2 aralkyl group has one or two carbon atoms in the alkyl portion.
• Pharmaceutically acceptable salts include acid salts of a disclosed RNase L activator containing an amine or other basic group and can be obtained by reacting the compound with a suitable organic or inorganic acid, such as hydrogen chloride, hydrogen bromide, acetic acid, perchloric acid and the like.
• salts include sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, tartrates [e.g. (+)-tartrates, (-)-tartrates or mixtures thereof including racemic mixtures], succinates, benzoates and salts with amino acids such as glutamic acid.
• Salts of a disclosed RNase L activator containing a carboxylic acid or other acidic functional group can be prepared by reacting with a suitable base.
• a suitable base which affords a pharmaceutically acceptable cation, which includes alkali metal salts (especially sodium and potassium), alkaline earth metal salts (especially calcium and magnesium), aluminum salts and ammonium salts, as well as salts made from physiologically acceptable organic bases such as trimethylamine, triethylamine, morpholine, pyridine, piperidine, picoline, dicyclohexylamine, N,N'- dibenzylethylenediamine, 2-hydroxyethylamine, bis-(2-hydroxyethyl)amine, tri-(2- hydroxyethyl)amine, procaine, dibenzylpiperidine, N-benzyl- ⁇ -phenethylamine, dehydroabietylamine, N,N'-bisdehydroabietylamine, glucamine, N
• Treatment or “treating” refers to both therapeutic and prophylactic treatment.
• an “effective amount” is the quantity of a disclosed RNase L activator in which a beneficial clinical outcome (prophylactic or therapeutic) is achieved when the compound is administered to a subject in need of treatment.
• a "beneficial clinical outcome” includes a reduction in the severity of the symptoms associated with the disease (e.g., fever), a reduction in the longevity of the disease and/or a delay in the onset of the symptoms associated with the disease compared with the absence of the treatment.
• a beneficial clinical outcome includes a reduction in tumor mass, a reduction in the rate of tumor growth, a reduction in metastasis, a reduction in the severity of the symptoms associated with the cancer and/or an increase in the longevity of the subject compared with the absence of the treatment.
• a "beneficial clinical outcome” includes a slowing or reduction in the narrowing of a blood vessel which has undergone angioplasty.
• the precise amount of a disclosed RNase L activator administered to a subject will depend on the type and severity of the disease or condition and on the characteristics of the subject, such as general health, age, sex, body weight and tolerance to drugs. It will also depend on the degree, severity and type of disease or condition. The skilled artisan will be able to determine appropriate dosages depending on these and other factors. Effective amounts of the disclosed RNase L activator typically range between about O.lmg/kg body weight per day and about 1000 mg/kg body weight per day, and preferably between 1 mg/kg body weight per day and 100 mg/kg body weight per day.
• the disclosed RNase L activator or salts thereof can be combined with a suitable solid or liquid carrier or diluent to form capsules, tablets, pills, powders, syrups, solutions, suspensions and the like.
• the tablets, pills, capsules, and the like contain from about 1 to about 99 weight percent of the active ingredient and a binder such as gum tragacanth, acacias, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose lactose or saccharin.
• a dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil.
• the disclosed RNase L activators or salts thereof can be combined with sterile aqueous or organic media to form injectable solutions or suspensions.
• aqueous or organic media for example, solutions in sesame or peanut oil, aqueous propylene glycol and the like can be used, as well as aqueous solutions of water-soluble pharmaceutically-acceptable salts of the compounds.
• Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
• the disclosed RNase L activators may also be formulated as a long acting formulation, such as a depot preparation.
• Such long acting formulations may be administered by implantation, or, for example, subcutaneously by intramuscular injection.
• RNase L activators or pharmaceutical formulations containing these compounds are in unit dosage form for administration to a mammal.
• the unit dosage form can be any unit dosage form known in the art including, for example, a capsule, an IV bag, a tablet, or a vial.
• the quantity of the disclosed RNase L activator in a unit dose of composition is an effective amount and may be varied according to the particular treatment involved. It may be appreciated that it may be necessary to make routine variations to the dosage depending on the age and condition of the patient.
• the dosage will also depend on the route of administration which may be by a variety of routes including oral, aerosol, rectal, transdermal, subcutaneous, intravenous, intramuscular, intraperitoneal and intranasal.
• Phosphonate compound XVIII will be prepared as shown in Scheme 4.
• Commercially available 3-aminophenol (XIII) will be protected via Standard methodology with dibenzylpyrocarbonate in dioxane/H 2 0 (1 :1) with NaOH or Et 3 N (to yield XIV).
• Deprotonation of the protected aminophenol with sodium hydride and coupling with the previously described p-toluenesulfonyloxymethane phosphonate in DMF to yield compound XV
• is followed by removal of the benzyloxycarbonyl protective group by transfer hydrogenation to yield compound XVI).
• the assay is based on fluorescence resonance energy transfer (FRET).
• FRET fluorescence resonance energy transfer
• the method includes recombinant human RNase L produced in insect cells, from a baculovirus vector, and purified by FPLC (Thakur CS, Xu Z, Wang Z, Novince Z, Silverman RIi. A convenient and sensitive fluorescence resonance energy transfer assay for RNase L and 2",5' oligoadenylates. Methods MoI Med 2005;116:103-13).
• the cleavable RNA substrate is a 36-nucleotide synthetic oligoribonucleotide with a fluorophore (6-carboxyfluorescein, FAM) at the 5'-terminus and a quencher (black hole quencher-1, BHQl), at the 3'-terminus.
• FAM 6-carboxyfluorescein
• BHQl black hole quencher-1
• the RNA sequence is from the intergenic region of the paramyxovirus, respiratory syncytial virus (RSV) genomic RNA.
• the RSV sequence was chosen because it contains several cleavage sites for RNase L (UU or UA) in an optimal context for cleavage.
• RNA cleavage reactions were performed in 96-well black microtiter plates containing RNase L, the cleavable FRET RNA substrate and 2-5A.
• the EC 50 is routinely obtained (concentration of activator to give 50% maximum activation) of 0.3 nM with authentic trimer 2-5A [p3A(2'p5'A) 2 ] as the activator of RNase L (Fig. IA).
• the dephosphorylated trimer, A(2'p5'A) 2 was unable to activate RNase L, consistent with prior findings (Fig. 1 A&D).
• RNA substrates Two different P- labeled RNA substrates (Fig. 3A&B).
• 25 ⁇ M of compound 1 (Fig. 3A, lanes 3&4)
• 25 ⁇ M compound 2 (Fig. 3A, lanes 5&6) were incubated in the presence and absence of purified human RNase L with the synthetic RNA substrate GGACUUUUUUUCCCUUUUUUUCC-[ 32 P]pCp (SEQ ID NO.: 1).
• RNase L activated by 2-5 A or compounds 1 or 2 cleaved the substrate on the 3' side of the UU dinucleotide sequence, consistent with our FRET assay findings.
• RNase L activation by lead compounds 1 and 2 was further supported using a sequence specific substrate C 7 U 2 C 12 (Fig. 3B) (SEQ ID NO.: 2).
• Compound 1 (25 ⁇ M) (lanes 4&5), and compound 2 (25 ⁇ M) (lanes 6&7) were separately incubated in the presence and absence of RNase L with the radiolabeled RNA substrate.
• RNase L activated by 2-5 A, compound 1 or compound 2 cleaved the substrate on the 3 '-side of the UU dinucleotide sequence. In the absence of activator no product band was detected.
• RNase L dimerization is a prerequisite for the nuclease activation.
• protein cross-linking assays were performed (Fig. 3C).
• the oligomeric state of RNase L was determined in western blots probed with monoclonal antibody against RNase L.
• Monomer RNase L converted to dimer in the presence of 2-5 A, compound 1, or compound 2 (Fig. 3C).
• Sensograms were recorded and the maximum resonance units (Rmax) at equilibrium were plotted as a function of the compound concentrations using Bia- evaluationTM software (Fig. 4). A dose-dependent decrease in the resonance response occurred with either compound 1 or 2. The data indicate that these compounds compete with 2-5 A for RNase L binding. Analysis of the data indicated that the binding constants (KJ) for compounds 1 and 2 are 18 ⁇ M and 12 ⁇ M, respectively.
• Cytotoxicity of compounds 1 and 2 was evaluated by MTS (tetrazolium) conversion assays (Promega). Treatments with compound 1 at 50 ⁇ M for 3 days reduced cell viability to 76.3% and 98.2% of control (untreated) levels for DU145 and HeLa cells, respectively. Treatments with compound 2 (also at 50 ⁇ M for 3 d) reduced cell viability as a percentage of untreated cells to 95.2% and 86.5% for DU145 and HeLa cells, respectively. The results for DU145 cells are shown in Figure 5; and the results for HeIa M cells are shown in Figure 6. As can be seen from the results, these compounds lack significant cytotoxcity.
• Example 6 Compound 2 Shows Antiviral Activity against Parainfluenza Virus 3,
• Picornavirus and Encephalomyocarditis Virus To determine antiviral activity, cells were infected with a recombinant human parainfluenza virus 3 (HPIV3) in which green fluorescent protein (GFP) cDNA was inserted between the P and M genes (provided by collaborator A. Banerjee) (Fig. 7).
• the cell lines used are HeLa M cells which are deficient in RNase L or HeLa M cells stably expressing either wild type RNase L or a nuclease-dead mutant (R667A) RNase L (from a CMV promoter in vector pcDNAneo). Cells were infected at an MOI of 0.1 with HPIV3/GFP in serum free medium (DMEM) for Ih.
• DMEM serum free medium
• the proliferation of the clonal cell line AlO was determined using the colorimetric CellTiter 96 ® AQ ueO us Cell Proliferation Assay as described (Promega).
• This method uses the tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4- sulfophenyl)-2H-tetrazolium, MTS] and phenazine methosulfate (PMS), an electron coupling reagent.
• Immortalized mouse embryonic fibroblasts were grown in RPMI supplemented with 10% FBS and p/s.
• Baby hamster kidney (BHK21) cells and african green monkey kidney cells (BSC40) were grown in Dulbecco's modified
• MOI Vaccinia Virus (Western Reserve) 5 PFU using no media serum for infection (virus stock: lxl0 9 PFU/ml)
• BHK21 cells were plated in 12 well plates, complete monolayer of the cells were infected with different dilutions of virus using serum free media. After 45min post infection, media was removed and the cells washed twice with PBS and replaced with Agar media [mix of 2% agarose + (2x MEM + 20%FBS)], after two days second layer of agar media was added with 0.05% neutral red in order to count the plaques.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Virology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Molecular Biology (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Biotechnology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pulmonology (AREA)
• AIDS & HIV (AREA)
• Urology & Nephrology (AREA)
• Vascular Medicine (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Tropical Medicine & Parasitology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
• Thiazole And Isothizaole Compounds (AREA)
• Heterocyclic Compounds Containing Sulfur Atoms (AREA)
• Enzymes And Modification Thereof (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=38374152

Family Applications (1)

Country Status (10)

Families Citing this family (9)

Family Cites Families (6)

• 2007
  • 2007-04-25 RU RU2008146422/04A patent/RU2008146422A/ru not_active Application Discontinuation
  • 2007-04-25 WO PCT/US2007/009959 patent/WO2007127212A2/en active Application Filing
  • 2007-04-25 JP JP2009507765A patent/JP2009536622A/ja not_active Withdrawn
  • 2007-04-25 MX MX2008013668A patent/MX2008013668A/es not_active Application Discontinuation
  • 2007-04-25 CN CNA2007800208258A patent/CN101460471A/zh active Pending
  • 2007-04-25 AU AU2007243403A patent/AU2007243403A1/en not_active Abandoned
  • 2007-04-25 EP EP07755981A patent/EP2016062A2/de not_active Withdrawn
  • 2007-04-25 KR KR1020087028782A patent/KR20090007609A/ko not_active Application Discontinuation
  • 2007-04-25 CA CA002650028A patent/CA2650028A1/en not_active Abandoned
• 2008
  • 2008-10-23 IL IL194890A patent/IL194890A0/en unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events